human diagnostic News
-
Atmo Biosciences wins Early Stage Investment Forum at AusBiotech
Atmo Biosciences beat 10 other contenders to win the Early Stage Investment Forum (ESIF) at AusBiotech 2019, held at the Melbourne Convention Centre last week. The ESIF is a key element of the annual AusBiotech conference featuring short pitches from SMEs and research institutions on early stage biotech technology and projects covering areas such as: Human therapeutics Diagnostics Medical ...
-
Lifespin Announces Expansion of Laboratory Testing Capability
Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespin’s annual laboratory testing capacity. Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples ...
-
Extraction-free PCR testing for SARS-CoV-2
The OPTI SARS-CoV-2 RT-PCR Test has received FDA Emergency Use Authorization and CE-IVD for sample handling using the OPTI Rapid Lysis Buffer. The OPTI Rapid Lysis Buffer protocol eliminates the need for magnetic bead or spin column extraction and prepares the samples for PCR testing using a simple heating protocol. The OPTI Rapid Lysis Buffer has shown a diagnostic sensitivity and specificity of ...
-
Amerigo Scientific Launches New Polyclonal Antibody to Human Blood Coagulation Factor XIII
Amerigo Scientific, a distributor focused on providing critical products and services to the biomedical and life science communities, recently announced the launch of its new polyclonal antibody to human blood coagulation factor XIII to support researchers in life science fields for the detection of blood coagulation factor XIII. This antibody is used for research only, not for human, therapeutic ...
-
C2N Diagnostics Statement on FDA Accelerated Approval of Aducanumab forAlzheimer’s Treatment
C2N Diagnostics says the U.S. Food and Drug Administration’s (FDA) decision granting accelerated approval to aducanumab (Aduhelm) on the basis of amyloid plaque reduction for Alzheimer’s treatment represents a significant change in the ongoing fight against the horrible disease. Dr. Joel Braunstein, C2N’s CEO, said, “The accelerated approval of aducanumab will offer a ...
-
OPTI Medical Systems Receives US FDA Emergency Use Authorization for Its OPTI SARS-CoV-2 RNA PCR Test Kit for Detection of the Virus Causing COVID-19
OPTI Medical Systems, Inc., a subsidiary of IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced that the United States Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the OPTI SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2, the virus that causes COVID-19. This announcement follows earlier validation of the test by the Institut ...
-
OPTI Medical Systems Receives CE Mark for Its OPTI SARS-CoV-2 RNA PCR Test Kit for Detection of the Virus Causing COVID-19
OPTI Medical Systems, Inc., a subsidiary of IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced that it has received the CE mark certification in the European Union for its OPTI SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2, the virus that causes COVID-19. This announcement follows earlier validation of the test by the Institut Pasteur of France as well as Emergency ...
-
Peer-Reviewed Journal Publishes Analytical Validation Results for the PrecivityAD Blood Test, Which Can Help Clinicians Detect Alzheimer’s Disease
C2N Diagnostics, which offers the PrecivityAD™ blood test that can help detect if certain markers for Alzheimer’s disease are in the brain, now has its analytical validation results available for review. The study appears in Clinica Chimica Acta, the official peer-reviewed journal of the International Federation of Clinical Chemistry and Laboratory Medicine. The article is titled ...
-
Rhode Island Patients Now Have Access to Breakthrough Alzheimer’s Diagnostic Blood Test
C2N Diagnostics, which offers the first widely accessible blood test to help physicians with Alzheimer’s disease diagnosis, announces that Rhode Island physicians can now use PrecivityAD™ to aid in the evaluation of their patients showing cognitive impairment. Rhode Island has joined 46 other states, the District of Columbia and Puerto Rico in granting C2N Diagnostics a CLIA ...
-
Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement
Offer price increased from €39.00 to €43.00 per QIAGEN share in cash Minimum acceptance threshold lowered from 75% to 66.67% of outstanding QIAGEN shares QIAGEN Supervisory and Managing Boards reaffirm unanimous recommendation that QIAGEN shareholders tender all of their QIAGEN shares Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. ...
-
Peer-Reviewed Journal Publishes PrecivityAD™ Blood Test Research, Confirming Its Role in Assisting Clinicians in Alzheimer’s Diagnosis
A peer-reviewed journal has published the first research paper to state that the PrecivityAD™ blood test “can accurately identify brain amyloid status based on a single blood sample.” The research paper in Molecular Neurodegeneration adds that the test’s “excellent performance” for Alzheimer’s disease (AD) diagnosis allows for “improved medical ...
-
Heska to Acquire LightDeck Diagnostics to Invest in Manufacturing Capabilities and Accelerate Research and Development Efforts
Heska Corporation (NASDAQ: HSKA; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics (“LightDeck”), a pioneer in innovative planar waveguide ...
-
Two Research Studies Bolster Method That C2N’s PrecivityAD Blood Test Uses to Aid Clinicians in Alzheimer’s Disease Diagnoses
Two recent studies demonstrated that the scientific method that serves as the basis for C2N Diagnostics’ PrecivityAD™ blood test scored best compared to others assays in their respective ability to identify amyloid plaque. The C2N Diagnostics PrecivityAD™ blood test that clinicians use to aid in diagnosing Alzheimer’s disease is underpinned by the liquid ...
-
StemBioSys expands its human chondrocyte offerings
StemBioSys introduced a new culture system designed to help investigators grow human chondrocytes in vitro faster while retaining a natural phenotype. The kit is comprised of CELLvo™ Matrix, a cell-derived extracellular matrix that mimics the chondrocytes’ natural microenvironment, and CELLvo™ Human Articular Chondrocytes, a collection of human chondrocytes sourced from donors ...
-
C2N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology
On World Alzheimer’s Day, Missouri leaders and economic development officials praise C2N Diagnostics for deciding to continue to grow its St. Louis-based company which is receiving international recognition for developing and accelerating novel diagnostics and therapies for Alzheimer’s disease. C2N Diagnostics has expanded its lab facilities to 13,320 square feet in the Cortex ...
-
Simplify Your Microbiome Research with MicrobioSeq’s Microbial Biomarker Discovery Service
MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA. The product manager is pleased to announce the launch of its Microbial Biomarker Discovery service, a revolutionary solution that promises to transform microbiology research. Microbiome research has rapidly gained momentum in recent years as scientists have come to appreciate the vital role ...
By CD Genomics
-
xCures and mProbe partner to help cancer patients determine optimal treatments
xCures, Inc. is proud to announce their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to transform the diagnosis, prevention, and treatment of complex diseases such as cancer. As the knowledge of cancer and its treatments advance, it is ever ...
By xCures
-
Alzheimer’s Breakthrough: C2N First to Offer a Widely Accessible Blood Test
Who Want Earlier Answers Patients, advocates, and physicians who have long awaited an easy to administer blood test that can help them better understand Alzheimer’s disease now have a health care innovation which they can rely upon. A breakthrough in Alzheimer’s disease has arrived with the introduction of C2N Diagnostics’ PrecivityAD™ blood test into the clinic. ...
-
Getting Personal with Precision Medicine – PharmaVOICE
Research on biologics, the study of the human genome, and the development of precision diagnostic tools and software have led to new hopes for the development of promising precision medicine. At the same time, the life-sciences commercial sector is still struggling with the challenges of payment structures and value assessment frameworks. As originally conceived, personalized medicine referred ...
By NeuroPointDX
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you